McCamish Mark Anthony 4

What Happened

• Mark Anthony McCamish, a director of Avadel Pharmaceuticals plc (AVDL), executed a gift transaction on February 4, 2026, transferring 67,025 Avadel shares. The transfer was recorded at $0.00 per share (gift), so no cash proceeds were involved. The filing shows the shares were moved from Matthew 5 LLC to the McCamish Charitable Remainder Trust.

Key Details

• Transaction date: February 4, 2026 — Transaction code: G (Gift); price reported: $0.00 per share.
• Shares transferred: 67,025 shares (disposed from Matthew 5 LLC; acquired by McCamish Charitable Remainder Trust).
• Ownership after transaction: The filing indicates the shares moved between entities controlled by or related to the reporting person. The filing disclaims direct beneficial ownership except for any pecuniary interest the reporting person and spouse may have as income beneficiaries of the trust.
• Notable footnotes:
  • The 67,025 shares were transferred from Matthew 5 LLC to the McCamish Charitable Remainder Trust.
  • Matthew 5 LLC is wholly owned by the Mark & Barbara McCamish Family Trust; the reporting person is manager of Matthew 5 LLC.
  • The McCamish Charitable Remainder Trust lists the reporting person and his spouse as income beneficiaries; the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
• Filing timeliness: No late filing flag indicated in the provided information.

Context

• Gifts are typically estate-planning or philanthropic moves and do not necessarily signal the insider’s view on the company’s stock. Here, shares were moved from an LLC controlled by the McCamish family to a charitable remainder trust that benefits the reporting person and spouse, which commonly reflects tax or estate-planning considerations rather than a market belief.